Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health.
Company profile
Ticker
BHC
Exchange
Website
CEO
Thomas J. Appio
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
BIOVAIL Corp, BIOVAIL CORP INTERNATIONAL, BIOVAIL CORPORATION INTERNATIONAL, Valeant Pharmaceuticals International, Inc.
SEC CIK
Corporate docs
Subsidiaries
Bausch & Lomb Argentina S.R.L. • Waicon Vision S.A. • Bausch & Lomb (Australia) Pty Limited • Bausch Health Australia Pty Limited • Wirra Holdings Pty Limited • Bausch & Lomb Australia Holdings Pty Limited • Solta Medical Australia Pty Limited • AcuFocus Australia • BAUSCH HEALTH LLC • Bausch & Lomb Pharma S.A. ...
BHC stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
17 May 23
10-Q
2023 Q1
Quarterly report
4 May 23
8-K
Bausch Health Announces First-quarter 2023 Results
4 May 23
ARS
2022 FY
Annual report to shareholders
6 Apr 23
DEFA14A
Additional proxy soliciting materials
6 Apr 23
DEF 14A
Definitive proxy
6 Apr 23
8-K
Bausch Health Announces Changes to its Board of Directors
1 Mar 23
10-K
2022 FY
Annual report
23 Feb 23
8-K
Bausch Health Announces Fourth-quarter and Full-year 2022 Results
23 Feb 23
8-K
Regulation FD Disclosure
15 Feb 23
Transcripts
BHC
Earnings call transcript
2023 Q1
4 May 23
BHC
Earnings call transcript
2023 Q1
4 May 23
BHC
Earnings call transcript
2022 Q4
23 Feb 23
BHC
Earnings call transcript
2022 Q4
23 Feb 23
BHC
Earnings call transcript
2022 Q3
3 Nov 22
BHC
Earnings call transcript
2022 Q2
9 Aug 22
BHC
Earnings call transcript
2022 Q2
9 Aug 22
BHC
Earnings call transcript
2022 Q1
10 May 22
BHC
Earnings call transcript
2022 Q1
10 May 22
BHC
Earnings call transcript
2021 Q4
23 Feb 22
Latest ownership filings
Financial summary
| Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 531.00 mm | 531.00 mm | 531.00 mm | 531.00 mm | 531.00 mm | 531.00 mm |
| Cash burn (monthly) | 20.00 mm | 160.75 mm | (no burn) | (no burn) | (no burn) | 42.58 mm |
| Cash used (since last report) | 41.18 mm | 330.96 mm | n/a | n/a | n/a | 87.67 mm |
| Cash remaining | 489.82 mm | 200.04 mm | n/a | n/a | n/a | 443.33 mm |
| Runway (months of cash) | 24.5 | 1.2 | n/a | n/a | n/a | 10.4 |
Institutional ownership, Q1 2023
75.0% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 231 |
| Opened positions | 29 |
| Closed positions | 64 |
| Increased positions | 51 |
| Reduced positions | 81 |
| 13F shares | Current |
|---|---|
| Total value | 2.07 tn |
| Total shares | 271.32 mm |
| Total puts | 31.92 mm |
| Total calls | 10.59 mm |
| Total put/call ratio | 3.0 |
| Largest owners | Shares | Value |
|---|---|---|
| Icahn Carl C Et Al | 34.72 mm | $279.99 bn |
| Paulson & Co. | 26.44 mm | $214.16 bn |
| BEN Franklin Resources | 16.60 mm | $134.49 bn |
| Goldentree Asset Management | 16.53 mm | $133.92 bn |
| VA Partners I | 14.43 mm | $135.65 mm |
| National Bank of Canada | 13.14 mm | $106.45 bn |
| Hudson Bay Capital Management | 11.50 mm | $93.15 bn |
| Vanguard | 11.13 mm | $90.13 bn |
| Healthcare Of Ontario Pension Plan Trust Fund | 10.00 mm | $81.00 bn |
| Laurion Capital Management | 9.84 mm | $79.69 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 19 May 23 | Brett Icahn | Common Shares, No Par Value | Grant | Acquire A | No | No | 0 | 29,205 | 0.00 | 93,079 |
| 19 May 23 | Kavanagh Sarah B | Common Shares, No Par Value | Grant | Acquire A | No | No | 0 | 29,205 | 0.00 | 146,652 |
| 19 May 23 | Steven D Miller | Common Shares, No Par Value | Grant | Acquire A | No | No | 0 | 29,205 | 0.00 | 139,517 |
| 19 May 23 | Mulligan Richard | Common Shares, No Par Value | Grant | Acquire A | No | No | 0 | 29,205 | 0.00 | 65,909 |
| 19 May 23 | Power Robert N | Common Shares, No Par Value | Grant | Acquire A | No | No | 0 | 29,205 | 0.00 | 165,016 |
News
Jefferies Maintains Buy on Bausch Health Companies, Raises Price Target to $9.5
22 May 23
Bausch Health Options Traders: Stock Will Remain Below This Level Through July Expiration
18 May 23
New Clinical Study Suggests The Use Of OraPharma's ARESTIN Microspheres, 1mg May Decrease Certain Pathogens In Adults With Periodontitis
18 May 23
Watching Bausch Health Companies; Seeking Alpha Reports, Court Ruling In Patent Dispute With Norwich Pharma; Court Issued An Order Denying Norwich's Motion To Modify Judgment In The Case Of: "Salix Pharmaceuticals, Ltd. Norwich Pharmaceuticals, Inc."
17 May 23
Bausch Health Companies Stock Halted On Circuit Breaker To The Upside On The Toronto Stock Exchange (TSX)
17 May 23
Press releases
OraPharma and Alex Rodriguez Team Up to Raise Awareness About the Importance of Managing Gum Disease
31 May 23
Thinking about buying stock in Applied Digital, StoneCo, Mereo BioPharma, Confluent, or Bausch Health?
18 May 23
New Clinical Study Suggests the Use of OraPharma's ARESTIN(R) (minocycline HCl) Microspheres, 1mg May Decrease Certain Pathogens in Adults with Periodontitis
18 May 23
U.S. District Court Upholds Final Judgment for XIFAXAN(R) 550 mg That Prevents FDA Approval of Norwich's Abbreviated New Drug Application Until 2029
17 May 23
Bausch Health Announces 2023 Annual Meeting of Shareholder Results
17 May 23